ArticlePharmaceuticals (Basel, Switzerland)2013
Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations.
Article in Pharmaceuticals (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Combination of tocolytic agents for inhibiting preterm labour.The Cochrane database of systematic reviews · 2014Pooled it
- Targeted downmodulation of OXTR and Cx43 in the myometrium by SERTIs as a novel tocolytic strategy.Uterine research · 2026Article
- The genetic architecture of cervical length is shared with spontaneous preterm birth risk.Communications medicine · 2025Article
- Article
- Article
- Nanomedicine strategies to improve therapeutic agents for the prevention and treatment of preterm birth and future directions.Nanoscale advances · 2023Review
- Landscape of Preterm Birth Therapeutics and a Path Forward.Journal of clinical medicine · 2021Review
- The relaxant effect of nicardipine on the isolated uterine smooth muscle of the pregnant rat.Anesthesia and pain medicine · 2019Article
- Efficacy and safety of oral nifedipine with or without vaginal progesterone in the management of threatened preterm labor.International journal of reproductive biomedicine · 2019Article
- Effect of Solanum Nigrun on Uterus of Non-gravid Rats.Ethiopian journal of health sciences · 2017Article
- Obesity in pregnancy: a novel concept on the roles of adipokines in uterine contractility.Croatian medical journal · 2017Review
- The effects of progesterone on the alpha2-adrenergic receptor subtypes in late-pregnant uterine contractions in vitro.Reproductive biology and endocrinology : RB&E · 2016Article
- Success rate in preterm uterine contraction inhibition with tocolytic agents in a tertiary care center.International journal of women's health · 2016Article
- Severe resistant maternal hypotension following tocolysis with nifedipine.BMJ case reports · 2014Article
- Computational modeling of inhibition of voltage-gated Ca channels: identification of different effects on uterine and cardiac action potentials.Frontiers in physiology · 2014Article
- Nicardipine-induced acute pulmonary edema: a rare but severe complication of tocolysis.Case reports in critical care · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydropyridine Ca2+ channel blockers (CCBs) are widely accepted in the treatment of premature labour. Their mechanism of action in tocolysis involves the blockade of L-type Ca2+ channels, influenced by the Ca2+-activated K+ channels, beta-adrenergic receptors (β-ARs) and sexual hormones. In clinical practice, most experience has been gained with the use of nifedipine, whose efficacy is superior or comparable to those of β-agonists and oxytocin antagonists. Additionally, it has a favourable adverse effect profile as compared with the majority of other tocolytics. The most frequent and well-tolerated side-effects of CCBs are tachycardia, headache and hypotension. In tocolytic therapy efforts are currently being made to find combinations of tocolytic agents that yield better therapeutic action. The available human and animal studies suggest that the combination of CCBs with β-AR agonists is beneficial, although such combinations can pose risk of pulmonary oedema in multiple pregnancies and maternal cardiovascular diseases. Preclinical data indicate the potential benefit of combinations of CCBs and oxytocin antagonists. However, the combinations of CCBs with progesterone or cyclooxygenase inhibitors may decrease their efficacy. The CCBs are likely to remain one of the most important groups of drugs for the rapid inhibition of premature uterine contractions. Their significance may be magnified by further clinical studies on their combined use for tocolysis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.